Analyses of Lymphoma Incidence Trends by Subtype Suggest Priorities for Future Research

NCI researchers found striking differences in incidence patterns and time trends by lymphoma subtype, age, sex, and race/ethnic group in a large U.S. population-based assessment published in the January 1 issue of Blood.



Although lymphoma is the fifth most common category of neoplasms in the United States, the causes of this group of diseases are largely unknown, noted scientists from NCI's Division of Cancer Epidemiology and Genetics (DCEG). The researchers analyzed almost 115,000 lymphoma cases diagnosed between 1992 and 2001 in 12 Surveillance, Epidemiology, and End Results (SEER) registries. The researchers used the 2001 World Health Organization lymphoma classification system in their analysis.



"Analyses of the incidence patterns and trends of the lymphoma subtypes in the general population can provide us with clues regarding etiology and suggest promising areas for future research," said Dr. Lindsay Morton, DCEG research fellow and lead author on the study.



For example, during the 10-year period, rates of diffuse large B-cell lymphoma and follicular lymphoma in the elderly increased 1.4 percent and 1.8 percent per year, respectively, whereas rates for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1 percent per year, suggesting that exposures to the still unknown causes of these lymphoma subtypes may have changed. The investigators also noted variation in the incidence of lymphoma subtypes by age. "These age differences suggest that the timing of key exposures may differ by subtype," Dr. Morton noted.



The study also included the first comprehensive analysis of lymphoma incidence patterns among Asian Americans, showing considerably lower rates for CLL/SLL and Hodgkin lymphoma. In contrast, whites had the highest burden for most subtypes, especially hairy cell leukemia and follicular lymphoma, whereas African Americans had the highest rates for plasma cell and T-cell lymphomas. Source: Latest NCI Newsletter

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap